Neurogene (NGNE) Change in Accured Expenses (2013 - 2026)

Neurogene (NGNE) has 14 years of Change in Accured Expenses data on file, last reported at $359000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 116.3% year-over-year to $359000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 4457.73% YoY) and the FY2025 annual result came in at $1.7 million, up 160.04% from the prior year.
• Change in Accured Expenses retreated to $359000.0 in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.6 million in Q3 2024 to a low of -$4.9 million in Q1 2024.
• A 5-year average of -$206882.4 and a median of $359000.0 in 2026 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 260.08% — and 2025, when it soared 949.28%.
• Tracing NGNE's Change in Accured Expenses over 5 years: stood at -$1.0 million in 2022, then slumped by 260.08% to -$3.7 million in 2023, then soared by 79.71% to -$743000.0 in 2024, then jumped by 279.14% to $1.3 million in 2025, then tumbled by 73.03% to $359000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $359000.0 (Q1 2026), $1.3 million (Q4 2025), and $365000.0 (Q3 2025), per Business Quant data.